Literature DB >> 12145681

Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.

V H J van der Velden1, D C H Jacobs, A J M Wijkhuijs, W M Comans-Bitter, M J Willemse, K Hählen, W A Kamps, E R van Wering, J J M van Dongen.   

Abstract

Sensitive and quantitative detection of minimal residual disease (MRD) in bone marrow (BM) samples of children with acute lymphoblastic leukemia (ALL) is essential for evaluation of early treatment response. In this study, we evaluated whether the traumatic BM samplings can be replaced by peripheral blood (PB) samplings. MRD levels were analyzed in follow-up samples of 62 children with precursor-B-ALL (532 paired BM-PB samples) and 22 children with T-ALL (149 paired BM-PB samples) using real-time quantitative PCR (RQ-PCR) analysis of immunoglobulin and T cell receptor gene rearrangements with sensitivities of 10(-3) to 10(-5) (one ALL cell in 10(3) to 10(5) normal cells). In 14 of the 22 T-ALL patients, detectable MRD levels were found in 67 paired BM-PB samples: in 47 pairs MRD was detected both in BM and PB, whereas in the remaining pairs very low MRD levels were detected in BM (n = 11) or PB (n = 9) only. The MRD levels in the paired BM-PB samples were very comparable and strongly correlated (r(s) = 0.849). Comparable results were obtained earlier by immunophenotyping in 26 T-ALL patients (321 paired BM-PB samples), which also showed a strong correlation between MRD levels in paired BM and PB samples (r(s) = 0.822). In 39 of the 62 precursor-B-ALL patients, MRD was detected in 107 BM-PB pairs: in 48 pairs MRD was detected in both BM and PB, in 47 pairs MRD was solely detected in BM (at variable levels), and in 12 pairs only the PB sample was MRD-positive at very low levels (</=10(-4)). Furthermore, in the 48 double-positive pairs, MRD levels in BM and PB varied enormously with MRD levels in BM being up to 1000 times higher than in the corresponding PB samples. Consequently, BM samples cannot easily be replaced by PB sampling for MRD analysis in childhood precursor-B-ALL, in line with their BM origin. In T-ALL, which are of thymic origin, BM sampling might be replaced by PB sampling, because the dissemination of T-ALL cells to BM and PB appears to be comparable.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145681     DOI: 10.1038/sj.leu.2402636

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  41 in total

Review 1.  Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts.

Authors:  Nicholas J Short; Elias Jabbour; Maher Albitar; Marcos de Lima; Lia Gore; Jeffrey Jorgensen; Aaron C Logan; Jae Park; Farhad Ravandi; Bijal Shah; Jerald Radich; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2018-11-26       Impact factor: 10.047

2.  Real-time PCR method for the quantitative analysis of human T-cell receptor gamma and beta gene rearrangements.

Authors:  J L Chain; M L Joachims; S W Hooker; A B Laurent; C K Knott-Craig; L F Thompson
Journal:  J Immunol Methods       Date:  2005-03-18       Impact factor: 2.303

3.  Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.

Authors:  Roger S Riley; David Williams; Micaela Ross; Shawn Zhao; Alden Chesney; Bradly D Clark; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

4.  Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis.

Authors:  Jana Volejnikova; Ester Mejstrikova; Tatana Valova; Leona Reznickova; Ladislava Hodonska; Vladimir Mihal; Jaroslav Sterba; Yahia Jabali; Daniela Prochazkova; Bohumir Blazek; Jiri Hak; Zdenka Cerna; Ondrej Hrusak; Jan Stary; Jan Trka; Eva Fronkova
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

5.  Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.

Authors:  Aaron C Logan; Nikita Vashi; Malek Faham; Victoria Carlton; Katherine Kong; Ismael Buño; Jianbiao Zheng; Martin Moorhead; Mark Klinger; Bing Zhang; Amna Waqar; James L Zehnder; David B Miklos
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-24       Impact factor: 5.742

Review 6.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

Authors:  Jacques J M van Dongen; Vincent H J van der Velden; Monika Brüggemann; Alberto Orfao
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

7.  Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.

Authors:  Olga Sala Torra; Megan Othus; David W Williamson; Brent Wood; Ilan Kirsch; Harlan Robins; Lan Beppu; Margaret R O'Donnell; Stephen J Forman; Frederick R Appelbaum; Jerald P Radich
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-03       Impact factor: 5.742

8.  Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.

Authors:  Stuart S Winter; Kimberly P Dunsmore; Meenakshi Devidas; Nancy Eisenberg; Barbara L Asselin; Brent L Wood; Marcia S Leonard Rn; John Murphy; Julie M Gastier-Foster; Andrew J Carroll; Nyla A Heerema; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; William L Carroll; Stephen P Hunger
Journal:  Pediatr Blood Cancer       Date:  2015-03-08       Impact factor: 3.167

9.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

10.  Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Stuart S Winter; Zeyu Jiang; Hadya M Khawaja; Timothy Griffin; Meenakshi Devidas; Barbara L Asselin; Richard S Larson
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.